Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note released on Friday. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Trading Up 1.9 %

BTX stock opened at $6.54 on Friday. The company has a market capitalization of $384.72 million, a P/E ratio of -2.88 and a beta of 4.61. The business has a 50 day simple moving average of $2.62 and a 200-day simple moving average of $1.51. Brooklyn ImmunoTherapeutics has a twelve month low of $6.35 and a twelve month high of $8.31.

Brooklyn ImmunoTherapeutics Dividend Announcement

The firm also recently announced a monthly dividend, which will be paid on Monday, March 31st. Stockholders of record on Friday, March 14th will be issued a $0.0862 dividend. The ex-dividend date is Friday, March 14th. This represents a $1.03 dividend on an annualized basis and a dividend yield of 15.81%. Brooklyn ImmunoTherapeutics’s payout ratio is -40.09%.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.